521 related articles for article (PubMed ID: 23547216)
1. Longterm effects of rituximab on B cell counts and autoantibody production in rheumatoid arthritis: use of high-sensitivity flow cytometry for more sensitive assessment of B cell depletion.
Váncsa A; Szabó Z; Szamosi S; Bodnár N; Végh E; Gergely L; Szucs G; Szántó S; Szekanecz Z
J Rheumatol; 2013 May; 40(5):565-71. PubMed ID: 23547216
[TBL] [Abstract][Full Text] [Related]
2. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.
Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Gabay C; van Riel PL; Nordström DC; Gomez-Reino J; Pavelka K; Tomsic M; Kvien TK; van Vollenhoven RF
Ann Rheum Dis; 2011 Sep; 70(9):1575-80. PubMed ID: 21571731
[TBL] [Abstract][Full Text] [Related]
3. The effect of B-cell depletion therapy on serological evidence of B-cell and plasmablast activation in patients with rheumatoid arthritis over multiple cycles of rituximab treatment.
Cambridge G; Perry HC; Nogueira L; Serre G; Parsons HM; De La Torre I; Dickson MC; Leandro MJ; Edwards JC
J Autoimmun; 2014 May; 50():67-76. PubMed ID: 24365380
[TBL] [Abstract][Full Text] [Related]
4. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis.
Bos WH; Bartelds GM; Wolbink GJ; de Koning MH; van de Stadt RJ; van Schaardenburg D; Dijkmans BA; Nurmohamed MT
J Rheumatol; 2008 Oct; 35(10):1972-7. PubMed ID: 18785316
[TBL] [Abstract][Full Text] [Related]
5. B cell depletion with rituximab in patients with rheumatoid arthritis: Multiplex bead array reveals the kinetics of IgG and IgA antibodies to citrullinated antigens.
Cambridge G; Leandro MJ; Lahey LJ; Fairhead T; Robinson WH; Sokolove J
J Autoimmun; 2016 Jun; 70():22-30. PubMed ID: 27055777
[TBL] [Abstract][Full Text] [Related]
6. Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis.
Sellam J; Rouanet S; Hendel-Chavez H; Abbed K; Sibilia J; Tebib J; Le Loët X; Combe B; Dougados M; Mariette X; Taoufik Y
Arthritis Rheum; 2011 Dec; 63(12):3692-701. PubMed ID: 22127692
[TBL] [Abstract][Full Text] [Related]
7. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
Finckh A; Ciurea A; Brulhart L; Kyburz D; Möller B; Dehler S; Revaz S; Dudler J; Gabay C;
Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098
[TBL] [Abstract][Full Text] [Related]
8. CCL19, a B cell chemokine, is related to the decrease of blood memory B cells and predicts the clinical response to rituximab in patients with rheumatoid arthritis.
Sellam J; Rouanet S; Hendel-Chavez H; Miceli-Richard C; Combe B; Sibilia J; Le Loët X; Tebib J; Jourdan R; Dougados M; Taoufik Y; Mariette X
Arthritis Rheum; 2013 Sep; 65(9):2253-61. PubMed ID: 23740460
[TBL] [Abstract][Full Text] [Related]
9. Missing Anticitrullinated Protein Antibody Does Not Affect Short-term Outcomes in Early Inflammatory Arthritis: From the Canadian Early Arthritis Cohort.
Shu J; Bykerk VP; Boire G; Haraoui B; Hitchon C; Thorne JC; Tin D; Keystone EC; Pope JE;
J Rheumatol; 2015 Nov; 42(11):2023-8. PubMed ID: 26329342
[TBL] [Abstract][Full Text] [Related]
10. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse.
Cambridge G; Stohl W; Leandro MJ; Migone TS; Hilbert DM; Edwards JC
Arthritis Rheum; 2006 Mar; 54(3):723-32. PubMed ID: 16508933
[TBL] [Abstract][Full Text] [Related]
11. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis.
Leandro MJ; Cambridge G; Ehrenstein MR; Edwards JC
Arthritis Rheum; 2006 Feb; 54(2):613-20. PubMed ID: 16447239
[TBL] [Abstract][Full Text] [Related]
12. Abatacept reduces levels of switched memory B cells, autoantibodies, and immunoglobulins in patients with rheumatoid arthritis.
Scarsi M; Paolini L; Ricotta D; Pedrini A; Piantoni S; Caimi L; Tincani A; Airò P
J Rheumatol; 2014 Apr; 41(4):666-72. PubMed ID: 24584924
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.
Teng YK; Levarht EW; Hashemi M; Bajema IM; Toes RE; Huizinga TW; van Laar JM
Arthritis Rheum; 2007 Dec; 56(12):3909-18. PubMed ID: 18050222
[TBL] [Abstract][Full Text] [Related]
14. Apoptotic effect of rituximab on peripheral blood B cells in rheumatoid arthritis.
Szodoray P; Alex P; Dandapani V; Nakken B; Pesina J; Kim X; Wallis GL; Wilson PC; Jonsson R; Centola M
Scand J Immunol; 2004; 60(1-2):209-18. PubMed ID: 15238091
[TBL] [Abstract][Full Text] [Related]
15. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis.
Cambridge G; Leandro MJ; Edwards JC; Ehrenstein MR; Salden M; Bodman-Smith M; Webster AD
Arthritis Rheum; 2003 Aug; 48(8):2146-54. PubMed ID: 12905467
[TBL] [Abstract][Full Text] [Related]
16. Predictive factors of rituximab response in rheumatoid arthritis: results from a French university hospital.
Couderc M; Mathieu S; Pereira B; Glace B; Soubrier M
Arthritis Care Res (Hoboken); 2013 Apr; 65(4):648-52. PubMed ID: 23045227
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register.
Soliman MM; Hyrich KL; Lunt M; Watson KD; Symmons DP; Ashcroft DM;
J Rheumatol; 2012 Feb; 39(2):240-6. PubMed ID: 22174201
[TBL] [Abstract][Full Text] [Related]
18. The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to infliximab in rheumatoid arthritis: an exploratory study.
Klaasen R; Cantaert T; Wijbrandts CA; Teitsma C; Gerlag DM; Out TA; de Nooijer MJ; Baeten D; Tak PP
Rheumatology (Oxford); 2011 Aug; 50(8):1487-93. PubMed ID: 21454308
[TBL] [Abstract][Full Text] [Related]
19. Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis.
Toubi E; Kessel A; Slobodin G; Boulman N; Pavlotzky E; Zisman D; Rozenbaum M; Rosner I
Ann Rheum Dis; 2007 Jun; 66(6):818-20. PubMed ID: 17148544
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers of good EULAR response to the B cell depletion therapy in all seropositive rheumatoid arthritis patients: clues for the pathogenesis.
Ferraccioli G; Tolusso B; Bobbio-Pallavicini F; Gremese E; Ravagnani V; Benucci M; Podestà E; Atzeni F; Mannocci A; Biasi D; Manfredi M; Sarzi-Puttini P; Laganà B; Montecucco C
PLoS One; 2012; 7(7):e40362. PubMed ID: 22859946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
